Two Sigma Advisers
CPRX

Two Sigma Advisers’s Catalyst Pharmaceutical CPRX Stock Holding History

Two Sigma Advisers’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,892
Closed -$217K – 2369
2024
Q3 		$217K Buy
+10,892
New +$202K ﹤0.01% 2037
2023
Q3 		– Sell
-633,392
Closed -$8.51M – 2420
2023
Q2 		$8.51M Sell
633,392
-944,300
-60% -$13.6M 0.02% 557
2023
Q1 		$26.2M Sell
1,577,692
-233,300
-13% -$3.85M 0.07% 267
2022
Q4 		$33.7M Buy
1,810,992
+207,500
+13% +$3.19M 0.09% 214
2022
Q3 		$20.6M Buy
1,603,492
+526,200
+49% +$6.24M 0.06% 314
2022
Q2 		$7.55M Sell
1,077,292
-156,700
-13% -$1.15M 0.02% 600
2022
Q1 		$10.2M Buy
1,233,992
+342,800
+38% +$2.42M 0.03% 512
2021
Q4 		$6.03M Buy
891,192
+485,000
+119% +$3.19M 0.02% 684
2021
Q3 		$2.15M Sell
406,192
-284,000
-41% -$1.55M 0.01% 1207
2021
Q2 		$3.97M Sell
690,192
-206,400
-23% -$1.07M 0.01% 965
2021
Q1 		$4.13M Buy
896,592
+168,200
+23% +$668K 0.01% 931
2020
Q4 		$2.43M Sell
728,392
-5,900
-0.8% -$19.8K 0.01% 1150
2020
Q3 		$2.18M Sell
734,292
-360,300
-33% -$1.41M 0.01% 1119
2020
Q2 		$5.06M Buy
1,094,592
+653,400
+148% +$2.94M 0.01% 790
2020
Q1 		$1.7M Sell
441,192
-15,900
-3% -$65.3K 0.01% 1202
2019
Q4 		$1.71M Buy
457,092
+444,200
+3,446% +$2.08M ﹤0.01% 1294
2019
Q3 		$68K Buy
+12,892
New +$68.7K ﹤0.01% 2137
2019
Q1 		– Sell
-10,000
Closed -$19K – 2319
2018
Q4 		$19K Sell
10,000
-48,200
-83% -$138K ﹤0.01% 2312
2018
Q3 		$220K Sell
58,200
-28,400
-33% -$89K ﹤0.01% 2055
2018
Q2 		$270K Buy
86,600
+20,300
+31% +$61.6K ﹤0.01% 2132
2018
Q1 		$158K Sell
66,300
-11,792
-15% -$39.2K ﹤0.01% 2175
2017
Q4 		$305K Buy
+78,092
New +$258K ﹤0.01% 1939

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Two Sigma Advisers's CPRX Position: Q4 2024 in Review

Two Sigma Advisers sold out of Catalyst Pharmaceutical (CPRX) in Q4 2024, closing a stake of 10,892 shares — an estimated $217K sold.

Two Sigma Advisers first reported a position in CPRX in Q4 2017 and held it in 22 quarters. The position peaked at $33.7M in Q4 2022. 336 funds tracked by Wall St. Rank hold CPRX as of Q4 2024.

  • Two Sigma Advisers reported no remaining Catalyst Pharmaceutical position as of Q4 2024 after selling out during the quarter.
  • Two Sigma Advisers sold 10,892 Catalyst Pharmaceutical shares in Q4 2024, an estimated $217K.
  • Two Sigma Advisers first reported a position in Catalyst Pharmaceutical in Q4 2017 and held it in 22 quarters.
  • Two Sigma Advisers's Catalyst Pharmaceutical position peaked at $33.7M in Q4 2022.
  • 336 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2024.

Based on Two Sigma Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.